You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 藥明生物(2269.HK)漲4.5% 獲多家機構看好
格隆匯 09-18 13:39
格隆匯9月18日丨藥明生物(2269.HK)收復昨日失地,現報193.3港元,漲幅4.49%,最新總市值2625.4億港元。大和研報指,藥明生物在中國和全球快速發展的生物製藥CDMO(合同研發生產組織)中具有強大的競爭力,同時公司將會受益於新冠疫苗的短缺,首予其“買入”評級,目標價300港元。麥格理認為,市場調查分析預期,中國的生物製藥市場在未來3年複合增長18%,而公司來自中國的收入增長應與市場相符,故中國市場會是公司短期重要增長動力。將公司目標價由153.56港元升至209.21港元,重申“跑贏大市”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account